Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Gross Margin (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Gross Margin for 5 consecutive years, with 91.61% as the latest value for Q4 2025.

  • On a quarterly basis, Gross Margin rose 67.0% to 91.61% in Q4 2025 year-over-year; TTM through Dec 2025 was 89.73%, a 0.0% change, with the full-year FY2025 number at 89.73%, changed 0.0% from a year prior.
  • Gross Margin was 91.61% for Q4 2025 at Rhythm Pharmaceuticals, up from 89.28% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 112.77% in Q4 2022 to a low of 50.0% in Q2 2021.
  • A 5-year average of 87.11% and a median of 88.53% in 2021 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: surged 3365bps in 2022, then crashed -2611bps in 2023.
  • Rhythm Pharmaceuticals' Gross Margin stood at 87.01% in 2021, then increased by 30bps to 112.77% in 2022, then decreased by -23bps to 86.66% in 2023, then increased by 5bps to 90.95% in 2024, then rose by 1bps to 91.61% in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Gross Margin are 91.61% (Q4 2025), 89.28% (Q3 2025), and 88.57% (Q2 2025).